Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
Advanced Melanoma Program: Honoring a Legacy
The SCI is establishing the Advanced Melanoma Program—a world-class advanced melanoma center of excellence on the West Coast.
SCI Innovation Awards
Congratulations to the October 2023 awardees!
Celebrating 45 Years of Excellence
Since its establishment in 1978, the Stanford Cancer Biology PhD Program has been dedicated to training the next generation of exceptional scientists who will significantly contribute to cancer research.
The Future of Cancer
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still!
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
-
Renowned tumor suppressor has prominent role in tissue repair, Stanford Medicine study finds
The tumor suppressor p53 has been in the limelight for decades. But its cancer-fighting function may be only a side effect of its role in tissue repair, a Stanford Medicine study finds.
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.